Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 237 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) February 7, 2019 El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... January 15, 2024 Holidays, Traditions and Grief December 21, 2020 Load more HOT NEWS Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast... Help seeking: Why isn’t it as simple as it might sound?
